BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu J. Therapeutic Applications of Mesenchymal Stem Cells for Systemic Lupus Erythematosus. In: Turksen K, editor. Cell Biology and Translational Medicine, Volume 2. Cham: Springer International Publishing; 2018. pp. 73-85. [DOI: 10.1007/5584_2018_212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hozhabri H, Piceci Sparascio F, Sohrabi H, Mousavifar L, Roy R, Scribano D, De Luca A, Ambrosi C, Sarshar M. The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting. Int J Environ Res Public Health 2020;17:E5648. [PMID: 32764417 DOI: 10.3390/ijerph17165648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
2 Li S, Wang Y, Wang Z, Chen L, Zuo B, Liu C, Sun D. Enhanced renoprotective effect of GDNF-modified adipose-derived mesenchymal stem cells on renal interstitial fibrosis. Stem Cell Res Ther 2021;12:27. [PMID: 33413640 DOI: 10.1186/s13287-020-02049-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Khandpur S, Gupta S, Gunaabalaji DR. Stem cell therapy in dermatology. Indian J Dermatol Venereol Leprol 2021;:1-15. [PMID: 34245532 DOI: 10.25259/IJDVL_19_20] [Reference Citation Analysis]
4 Merimi M, El-Majzoub R, Lagneaux L, Moussa Agha D, Bouhtit F, Meuleman N, Fahmi H, Lewalle P, Fayyad-Kazan M, Najar M. The Therapeutic Potential of Mesenchymal Stromal Cells for Regenerative Medicine: Current Knowledge and Future Understandings. Front Cell Dev Biol 2021;9:661532. [PMID: 34490235 DOI: 10.3389/fcell.2021.661532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Xu J, Chen J, Li W, Lian W, Huang J, Lai B, Li L, Huang Z. Additive Therapeutic Effects of Mesenchymal Stem Cells and IL-37 for Systemic Lupus Erythematosus. J Am Soc Nephrol 2020;31:54-65. [PMID: 31604808 DOI: 10.1681/ASN.2019050545] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
6 Lee HK, Kim EY, Kim HS, Park EJ, Lee HJ, Lee TY, Kim KS, Bae SC, Hong JT, Kim Y, Han SB. Effect of Human Mesenchymal Stem Cells on Xenogeneic T and B Cells Isolated from Lupus-Prone MRL.Fas lpr Mice. Stem Cells Int 2020;2020:5617192. [PMID: 32215018 DOI: 10.1155/2020/5617192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang Q, Xu Y, Xu J. Editorial: Targeting Heterogeneity of Mesenchymal Stem Cells. Front Cell Dev Biol 2022;10:894008. [DOI: 10.3389/fcell.2022.894008] [Reference Citation Analysis]
8 Lee HK, Kim HS, Pyo M, Park EJ, Jang S, Jun HW, Lee TY, Kim KS, Bae SC, Kim Y, Hong JT, Yun J, Han SB. Phorbol ester activates human mesenchymal stem cells to inhibit B cells and ameliorate lupus symptoms in MRL.Fas lpr mice. Theranostics 2020;10:10186-99. [PMID: 32929342 DOI: 10.7150/thno.46835] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Li D, Li X, Duan M, Dou Y, Feng Y, Nan N, Zhang W. MiR-153-3p induces immune dysregulation by inhibiting PELI1 expression in umbilical cord-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Autoimmunity 2020;53:201-9. [PMID: 32321315 DOI: 10.1080/08916934.2020.1750011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Brown C, McKee C, Bakshi S, Walker K, Hakman E, Halassy S, Svinarich D, Dodds R, Govind CK, Chaudhry GR. Mesenchymal stem cells: Cell therapy and regeneration potential. J Tissue Eng Regen Med. 2019;13:1738-1755. [PMID: 31216380 DOI: 10.1002/term.2914] [Cited by in Crossref: 109] [Cited by in F6Publishing: 114] [Article Influence: 36.3] [Reference Citation Analysis]